Financial Services Association, September 15 (Editor: Ga Chen) Risk warning factors have been eliminated, and a number of A-share listed companies have been “taken off the stars.” According to Choice statistics, 8 ST companies have successfully “removed their caps” in the second half of the year. The specific A-share list is mainly Hekeda, Orid, Wanlin Logistics, Xining Special Steel, Quanzhu Co., Ltd., Mogao Co., Ltd., Kangmei Pharmaceutical, and Xinhuo. The details are shown below:

Hekeda, whose main business is the R&D, design, production and sales of precision cleaning equipment and water treatment equipment, announced on September 6 that the company's stock trading will be suspended for one day on September 9, 2024 (Monday) and will resume trading on September 10 (Tuesday) 2024; the “Delisting Risk Warning” will be lifted from the opening of the market on September 10, 2024. After “breaking away from the stars and taking off the hat,” Keda closed the game on Thursday to win three straight games. Hekeda issued a change announcement on September 11. Although the company has opened up new business growth points, it may still face multiple uncertainties such as changes in industry policies, increased market competition, and management challenges in actual operation, and there is some uncertainty about business development. HeKeda said on an interactive platform on September 11 that the company carried out a strategic layout and investment in the field of intelligent equipment wiring in 2023, with the aim of opening up new business growth points while gradually consolidating technical initial research and self-production capabilities for core components. In the first half of 2024, it achieved operating income of 14.0759 million yuan, achieving certain results.

Xining Special Steel, which is mainly engaged in the smelting and rolling processing business of special steels, announced on July 16 that trading of the company's shares will be suspended for one day from the opening of the market on July 17 and will resume trading on July 18; other risk warnings for the company's shares will be withdrawn from the opening of the market on July 18. After “removing the cap”, Xining Special Steel closed higher or lower on July 18. Xining Special Steel released its semi-annual report on August 29. The net loss attributable to the parent company's owners for the first half of the year was 0.294 billion yuan. The net loss for the same period last year was 1.057 billion yuan, and the loss narrowed. Xining Special Steel also revealed that the company is the largest special steel production base in western China, a national-level innovative enterprise and an important national equipment supporting enterprise. A steel enterprise with a comprehensive production capacity of 2.1 million tons of steel and 2 million tons of steel per year.

Kangmei Pharmaceutical, which is mainly engaged in the production and sale of Chinese medicine tablets, chemicals, etc., announced on July 2 that the company's stock trading will be suspended for 1 day on July 3, resumed trading on July 4, and other risk warnings will be withdrawn. After “removing the cap”, Kangmei Pharmaceutical closed higher and lower on July 4. Kangmei Pharmaceutical released its semi-annual report on August 23. Net profit attributable to owners of the parent company for the first half of the year was 15.7603 million yuan, and the net loss for the same period last year was 0.126 billion yuan, turning a loss into a profit. Kangmei Pharmaceutical said on an interactive platform on August 30 that the company will continue to push forward the implementation of the “12355” strategic plan, establish an intelligent traditional Chinese medicine health brand enterprise with traditional Chinese medicine tablets as the core, and focus on the two main strategic lines of “building a full-chain characteristic industry of traditional Chinese medicine tablets” and “providing special medical and health services”, with the five major business sectors of traditional Chinese medicine, medical care, Chinese medicine city, health products and pharmaceutical business as the main body, innovating business formats and business growth models to optimize and adjust the regional industrial cluster layout.

Xinhao announced on June 30 that the company's stock trading will be suspended for one day on July 1, 2024, and trading will resume from the opening of the market on July 2, 2024. The company withdrew the delisting risk warning from the opening of the market on July 2, 2024. After “leaving the stars off”, the new market closed higher and lower on July 2. Xinhao released its 2024 semi-annual report on August 30. Operating income during the reporting period was 78.5303 million yuan, down 24.38% year on year; net profit attributable to shareholders of listed companies was 3.096 million yuan, down 74.49% year on year. Xinhao also revealed that the company makes full use of existing resources to explore diversified business. Both the Big Health Industry and the Automobile Industry are industries supported by national policies. The subsidiary Zero Health is authorized by Japan's Elaten Co., Ltd. to expand the Big Health business through the acquisition of Jiangmen; the subsidiary Xincheng Ford obtained authorization from Shanghai GM to achieve superior integration through the partner Yancheng Xincheng Automobile Sales & Service Co., Ltd.'s senior industry sales experience and high-quality customer resources. Currently, all of these businesses are developing steadily.